- Home
- CMPR vs MYGN Comparison
CMPR vs MYGN Comparison
Compare CMPR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- MYGN
- Stock Information
- Founded
- CMPR 1994
- MYGN 1991
- Country
- CMPR Ireland
- MYGN United States
- Employees
- CMPR N/A
- MYGN N/A
- Industry
- CMPR Publishing
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CMPR Consumer Discretionary
- MYGN Health Care
- Exchange
- CMPR Nasdaq
- MYGN Nasdaq
- Market Cap
- CMPR 2.5B
- MYGN 2.2B
- IPO Year
- CMPR N/A
- MYGN 1995
- Fundamental
- Price
- CMPR $79.95
- MYGN $26.47
- Analyst Decision
- CMPR Strong Buy
- MYGN Buy
- Analyst Count
- CMPR 2
- MYGN 12
- Target Price
- CMPR $119.50
- MYGN $28.18
- AVG Volume (30 Days)
- CMPR 174.3K
- MYGN 642.6K
- Earning Date
- CMPR 10-23-2024
- MYGN 11-04-2024
- Dividend Yield
- CMPR N/A
- MYGN N/A
- EPS Growth
- CMPR N/A
- MYGN N/A
- EPS
- CMPR 6.43
- MYGN N/A
- Revenue
- CMPR $3,291,856,000.00
- MYGN $802,200,000.00
- Revenue This Year
- CMPR $7.63
- MYGN $13.84
- Revenue Next Year
- CMPR $5.28
- MYGN $9.57
- P/E Ratio
- CMPR $12.49
- MYGN N/A
- Revenue Growth
- CMPR 6.89
- MYGN 14.78
- 52 Week Low
- CMPR $57.01
- MYGN $13.82
- 52 Week High
- CMPR $104.92
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CMPR 36.50
- MYGN 44.92
- Support Level
- CMPR $77.07
- MYGN $25.90
- Resistance Level
- CMPR $84.13
- MYGN $27.55
- Average True Range (ATR)
- CMPR 2.54
- MYGN 0.89
- MACD
- CMPR -0.47
- MYGN -0.08
- Stochastic Oscillator
- CMPR 16.51
- MYGN 16.76
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.